On Demand Education

Understanding IDgenetix®

Jun 2021

IDgenetix simplifies the concept of pharmacogenomics and its relevance to mental health.

Behnaz Sarrami, MS, PharmD, Medical Science Liaison (MSL)

Incorporating DecisionDx-Melanoma into Clinical Practice: Molecular Information for Personalized Management Decisions

Darrell S. Rigel, MD, FAAD Clinical Professor of Dermatology New York University Grossman Medical School


Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients with Barrett’s Esophagus

Jun 2020

A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.

Jon M Davison

Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Non-Dysplastic Barrett’s Esophagus: A Spatial-Temporal Analysis

Oct 2020

Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.

Nicola F Frei

Castle Biosciences Genomic Testing for Uveal Melanoma

Katherina Alsina, PhD

Gene Expression Profiling: A Diagnostic Ancillary Test To Aid In The Diagnosis Of Melanocytic Lesions

Dr. Barry White shares cases of challenging melanocytic lesions in which gene expression profiling (GEP) was utilized to inform the diagnosis when histopathological findings were insufficient to render a definitive diagnosis

Barry White

Utility of GEP in Difficult to Diagnose Melanocytic Lesions

Dr. Drazen Jukic presents challenging cases in which gene expression profiling (GEP) was utilized to inform the diagnosis of ambiguous melanocytic lesions.

Drazen Jukic

Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies

Feb 2022

Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.

Iyer PG, Codipilly DC, Chandar AK, Agarwal S, Wang KK, Leggett CL, Latuche LR, Schulte PJ

Barrett’s Esophagus Panel: Predicting Progression in Barrett’s Esophagus Recent Advances Webinar

A panel discussion on the clinical challenges associated with predicting progression to esophageal adenocarcinoma in patients with Barrett’s esophagus.

Sri Komanduri, MD, FASGE, AGAF Director of Endoscopy Northwestern University, David Diehl, MD, FACP, FASGE Director of Interventional Endoscopy Geisinger Health System, Prasad G. Iyer, MD, MS, FASGE, FACG, Gastroenterologist, Mayo Clinic

Risk Stratification and Management of Dysplastic Barrett’s Esophagus

Jun 2022

Risk stratification is important in managing BE patients and biomarker assays such as TissueCypher® are “ready for Prime Time” in identifying patients at high risk for progression.

TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*

Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).

Nicola Frei, Doctor of Medicine, Amsterdam UMC

Barrett’s Esophagus Panel: Establishing Individual Patient Risk for Progression to Esophageal Cancer

Understand how TissueCypher® predicts future development of HGD/EAC in patients with BE. Impacts patient-care decisions as demonstrated by case studies.

Sri Komanduri, MD, FASGE, AGAF Director of Endoscopy Northwestern University. Rhonda Souza, MD,Co-Director, Baylor Scott & White Health, Vani Konda, MD Medical Director Baylor Scott & White Health